You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

923 Results
Guidelines and Advice
Status: Current
ID: 17-4
Version: 2
Nov 2016
Document
New
Apr 2025
Document
New
Apr 2025
Guidelines and Advice
Status: Archived
ID: 17-8
Jan 2014
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Curative, Palliative
Funding:
New Drug Funding Program
    Dostarlimab - Primary Advanced or Recurrent MSI-H or dMMR Endometrial Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
dostarlimab,
PACLitaxel,
CARBOplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2025
Statistical Reports
Jun 2016
Statistical Reports
Jan 2018
Statistical Reports
Aug 2020
Statistical Reports
Nov 2022

Pages